Anixa Biosciences Depreciation & Amortization Growth & History (ANIX)
Anixa Biosciences's depreciation and amortization was $36,000 for fiscal 2025.
View full Anixa Biosciences company overviewAnixa Biosciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-10-31 | $36,000 | −$1,000 | −2.70% |
| 2024 | 2024-10-31 | $37,000 | −$9,000 | −19.57% |
| 2023 | 2023-10-31 | $46,000 | $4,000 | +9.52% |
| 2022 | 2022-10-31 | $42,000 | — | — |
| 2020 | 2020-10-31 | $38,276 | −$428,032 | −91.79% |
| 2019 | 2019-10-31 | $466,308 | $447,873 | +2429.47% |
| 2018 | 2018-10-31 | $18,435 | −$24,781 | −57.34% |
| 2017 | 2017-10-31 | $43,216 | $9,883 | +29.65% |
| 2016 | 2016-10-31 | $33,333 | $20,818 | +166.34% |
| 2015 | 2015-10-31 | $12,515 | — | — |
| 2012 | 2012-10-31 | $7,234 | −$743 | −9.31% |
| 2011 | 2011-10-31 | $7,977 | −$381 | −4.56% |
| 2010 | 2010-10-31 | $8,358 | — | — |
Anixa Biosciences quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-04-30 | $10,000 | $1,000 | +11.11% |
| Q1 2026 | 2026-01-31 | $10,000 | — | — |
| Q4 2025 | 2025-10-31 | $9,000 | — | — |
| Q3 2025 | 2025-07-31 | $9,000 | — | — |
| Q2 2025 | 2025-04-30 | $9,000 | — | — |
| Q3 2020 | 2020-07-31 | $8,858 | −$47,899 | −84.39% |
| Q2 2020 | 2020-04-30 | $14,420 | $2,442 | +20.39% |
| Q1 2020 | 2020-01-31 | $14,998 | $8,868 | +144.67% |
| Q3 2019 | 2019-07-31 | $56,757 | $51,712 | +1025.01% |
| Q2 2019 | 2019-04-30 | $11,978 | $9,000 | +302.22% |
| Q1 2019 | 2019-01-31 | $6,130 | $1,739 | +39.60% |
| Q3 2018 | 2018-07-31 | $5,045 | −$5,773 | −53.36% |
| Q2 2018 | 2018-04-30 | $2,978 | −$7,795 | −72.36% |
| Q1 2018 | 2018-01-31 | $4,391 | −$6,114 | −58.20% |
| Q3 2017 | 2017-07-31 | $10,818 | −$216 | −1.96% |
| Q2 2017 | 2017-04-30 | $10,773 | $741 | +7.39% |
| Q1 2017 | 2017-01-31 | $10,505 | $6,656 | +172.93% |
| Q3 2016 | 2016-07-31 | $11,034 | — | — |
| Q2 2016 | 2016-04-30 | $10,032 | — | — |
| Q1 2016 | 2016-01-31 | $3,849 | −$78,496 | −95.33% |
| Q1 2015 | 2015-01-31 | $82,345 | — | — |
| Q1 2013 | 2013-01-31 | $1,424 | −$653 | −31.44% |
| Q3 2012 | 2012-07-31 | $1,712 | −$295 | −14.70% |
| Q2 2012 | 2012-04-30 | $1,834 | −$221 | −10.75% |
| Q1 2012 | 2012-01-31 | $2,077 | $147 | +7.62% |
| Q3 2011 | 2011-07-31 | $2,007 | — | — |
| Q2 2011 | 2011-04-30 | $2,055 | — | — |
| Q1 2011 | 2011-01-31 | $1,930 | — | — |
Anixa Biosciences depreciation and amortization trends
Over the last five fiscal years, Anixa Biosciences's depreciation and amortization decreased from $38,276 to $36,000, a change of −$2,276. The latest reported quarter, Q2 2026, shows $10,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anixa Biosciences source filings ↗